107 related articles for article (PubMed ID: 10680732)
21. Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.
Bunting PS; Chong N; Holowaty EJ; Goel V
Clin Biochem; 1998 Aug; 31(6):501-11. PubMed ID: 9740973
[TBL] [Abstract][Full Text] [Related]
22. Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen.
Tai P; Tonita J; Woitas C; Zhu T; Joseph K; Skarsgard D
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e525-30. PubMed ID: 22483701
[TBL] [Abstract][Full Text] [Related]
23. Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics.
Ondrusova M; Ondrus D; Karabinos J; Muzik J; Kliment J; Gulis G
Tumori; 2011; 97(2):149-55. PubMed ID: 21617707
[TBL] [Abstract][Full Text] [Related]
24. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
25. The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland.
Seikkula HA; Kaipia AJ; Ryynänen H; Seppä K; Pitkäniemi JM; Malila NK; Boström PJ
Int J Cancer; 2018 Mar; 142(5):891-898. PubMed ID: 29044563
[TBL] [Abstract][Full Text] [Related]
26. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
[TBL] [Abstract][Full Text] [Related]
27. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
28. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
29. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.
Stenman UH; Hakama M; Knekt P; Aromaa A; Teppo L; Leinonen J
Lancet; 1994 Dec; 344(8937):1594-8. PubMed ID: 7527116
[TBL] [Abstract][Full Text] [Related]
30. International trends in prostate-cancer mortality in the "PSA ERA".
Oliver SE; May MT; Gunnell D
Int J Cancer; 2001 Jun; 92(6):893-8. PubMed ID: 11351313
[TBL] [Abstract][Full Text] [Related]
31. Changing Incidence and Stage Distribution of Prostate Cancer in a Lithuanian Population-Evidence from National PSA-Based Screening Program.
Patasius A; Smailyte G
Int J Environ Res Public Health; 2019 Dec; 16(23):. PubMed ID: 31816821
[TBL] [Abstract][Full Text] [Related]
32. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.
Coldman AJ; Phillips N; Pickles TA
CMAJ; 2003 Jan; 168(1):31-5. PubMed ID: 12515782
[TBL] [Abstract][Full Text] [Related]
33. Time trends in prostate cancer screening in Swiss primary care (2010 to 2017) - A retrospective study.
Zechmann S; Di Gangi S; Kaplan V; Meier R; Rosemann T; Valeri F; Senn O;
PLoS One; 2019; 14(6):e0217879. PubMed ID: 31194773
[TBL] [Abstract][Full Text] [Related]
34. Metastatic prostate cancer in the modern era of PSA screening.
Fontenot PA; Nehra A; Parker W; Wyre H; Mirza M; Duchene DA; Holzbeierlein J; Thrasher JB; Van Veldhuizen P; Lee EK
Int Braz J Urol; 2017; 43(3):416-421. PubMed ID: 28338310
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer in Italy before and during the 'PSA era': survival trend and prognostic determinants.
Quaglia A; Vercelli M; Puppo A; Casella C; Artioli E; Crocetti E; Falcini F; Ramazzotti V; Tagliabue G;
Eur J Cancer Prev; 2003 Apr; 12(2):145-52. PubMed ID: 12671538
[TBL] [Abstract][Full Text] [Related]
36. Rising incidence of prostate cancer in Scotland: increased risk or increased detection?
Brewster DH; Fraser LA; Harris V; Black RJ
BJU Int; 2000 Mar; 85(4):463-72; discussion 472-3. PubMed ID: 10691826
[TBL] [Abstract][Full Text] [Related]
37. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
38. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
40. Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening.
Dickinson J; Shane A; Tonelli M; Connor Gorber S; Joffres M; Singh H; Bell N
CMAJ Open; 2016; 4(1):E73-9. PubMed ID: 27280117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
